Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1359931 · FYE Dec 31 · no price history on file Price Price history unavailable — No prices available for TARA in [1900-01-01, 2026-08-19]. This symbol may require bring-your-own-key (BYOK) data. At a glance | Short interest7.6% of sh out | | Days to cover11.5d | | 13F net flow (QoQ)+9.86% | | Top-10 13F concentration56.5% | | Next report (est.)2026-11-14 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Earnings (TTM)-$70.0M | | ROE−31.6% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns No return windows available for TARA. Risk No risk analytics available for TARA. Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| JANUS HENDERSON GROUP PLC | 5.2M | $27M | 9.63% | +1.3% | | BlackRock, Inc. | 3.4M | $18M | 6.28% | +40.9% | | Velan Capital Investment Management LP | 2.8M | $15M | 5.24% | +0.0% | | MILLENNIUM MANAGEMENT LLC | 2.8M | $15M | 5.23% | +275.8% | | Blackstone Inc. | 2.3M | $12M | 4.19% | +18.6% | | VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $11M | 3.92% | new | | Sio Capital Management, LLC | 2.0M | $10M | 3.64% | +14.8% | | ACORN CAPITAL ADVISORS, LLC | 1.8M | $9M | 3.24% | +0.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-11 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-11 | −$0.36 | — | — | — | | 2026-03-31 | 2026-05-13 | −$0.31 | — | — | — | | 2025-09-30 | 2025-11-10 | −$0.31 | — | — | — | | 2025-06-30 | 2025-08-11 | −$0.35 | — | — | — |
As-reported XBRL · next 2026-11-14 est.ⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · — (licensed EOD) · spzco.com/methodology
|
